ES2091323T3 - Medios de contraste. - Google Patents

Medios de contraste.

Info

Publication number
ES2091323T3
ES2091323T3 ES91906843T ES91906843T ES2091323T3 ES 2091323 T3 ES2091323 T3 ES 2091323T3 ES 91906843 T ES91906843 T ES 91906843T ES 91906843 T ES91906843 T ES 91906843T ES 2091323 T3 ES2091323 T3 ES 2091323T3
Authority
ES
Spain
Prior art keywords
contrast media
contrast
complexes
rays
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91906843T
Other languages
English (en)
Inventor
Arne Berg
Torsten Almen
Klaus Dieter Krautwurst
Sook-Hui Kim
Pal Rongved
Jo Klaveness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed Imaging AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging AS filed Critical Nycomed Imaging AS
Application granted granted Critical
Publication of ES2091323T3 publication Critical patent/ES2091323T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
    • C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Liquid Crystal (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Devices For Indicating Variable Information By Combining Individual Elements (AREA)
  • Steroid Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Electric Propulsion And Braking For Vehicles (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Lubricants (AREA)

Abstract

LA INVENCION SE REFIERE AL USO COMO AGENTES MEJORADORES DEL CONTRASTE EN LA FORMACION DE IMAGENES MEDICAS, ESPECIALMENTE EN RAYOS X, DE COMPLEJOS MULTINUCLEARES, POR EJEMPLO COMPLEJOS TALES COMO W2O2((MU)2O)2, EN EL CUAL LA ENTIDAD COMPLEJADA COMPRENDE AL MENOS DOS ATOMOS MEJORADORES DEL CONTRASTE.
ES91906843T 1990-03-28 1991-03-27 Medios de contraste. Expired - Lifetime ES2091323T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909006977A GB9006977D0 (en) 1990-03-28 1990-03-28 Compositions

Publications (1)

Publication Number Publication Date
ES2091323T3 true ES2091323T3 (es) 1996-11-01

Family

ID=10673438

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91906843T Expired - Lifetime ES2091323T3 (es) 1990-03-28 1991-03-27 Medios de contraste.

Country Status (18)

Country Link
US (2) US5458869A (es)
EP (2) EP0521977B1 (es)
JP (1) JPH06507147A (es)
AT (1) ATE142508T1 (es)
AU (1) AU645796B2 (es)
CA (1) CA2079212A1 (es)
DE (1) DE69122092T2 (es)
DK (1) DK0521977T3 (es)
ES (1) ES2091323T3 (es)
FI (1) FI924297A7 (es)
GB (1) GB9006977D0 (es)
HK (1) HK219596A (es)
HU (2) HUT69168A (es)
LT (1) LT3535B (es)
LV (1) LV10056B (es)
NO (1) NO923739L (es)
SG (1) SG43931A1 (es)
WO (1) WO1991014460A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017215A1 (en) 1990-03-28 1992-10-15 Nycomed Salutar, Inc. Contrast media
GB9006977D0 (en) * 1990-03-28 1990-05-23 Nycomed As Compositions
DE69230400T2 (de) * 1991-03-27 2000-08-03 Nycomed Salutar Inc., Wayne Kontrastmittel
US5330742A (en) * 1991-08-05 1994-07-19 Mallinckrodt Medical, Inc. Methods and compositions for magnetic resonance imaging
AU670029B2 (en) * 1991-08-05 1996-07-04 Mallinckrodt Medical, Inc. Heavy metal clusters for use as imaging agents
US5364953A (en) * 1992-11-05 1994-11-15 Mallinckrodt Medical, Inc. High relaxivity, paramagnetic, metal clusters for magnetic resonance imaging
GB9407812D0 (en) * 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
GB9420390D0 (en) * 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
US5717121A (en) * 1995-06-07 1998-02-10 Nycomed Salutar, Inc. Preparation and use of contrast agents
GB9601340D0 (en) * 1996-01-23 1996-03-27 Nycomed Salutar Inc Contrast media
JP3839059B2 (ja) * 1996-02-14 2006-11-01 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴイ Ｘ線フィルタを有するｘ線検査装置
US5804161A (en) * 1996-05-14 1998-09-08 Nycomed Salutar Inc. Contrast agents
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
EP1140204A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6596259B1 (en) 1998-12-22 2003-07-22 University Of Puerto Rico Metal based cubane structure contained in an octanuclear complex stable over several oxidation states and a method of producing the same
US7807137B1 (en) 1998-12-22 2010-10-05 University Of Puerto Rico Iron-based contrast agent
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
CN1386118A (zh) 2000-06-01 2002-12-18 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
CA2427911A1 (en) 2000-11-03 2002-05-10 Bristol Myers Squibb Company Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
US7928278B2 (en) * 2001-06-12 2011-04-19 University Of Florida Research Foundation, Inc. Method and apparatus for producing near-infrared radiation
US6838074B2 (en) 2001-08-08 2005-01-04 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US7138104B2 (en) 2001-08-08 2006-11-21 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
US7485283B2 (en) 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
JP4322781B2 (ja) * 2004-11-08 2009-09-02 富士フイルム株式会社 撮像装置
WO2007005491A1 (en) * 2005-06-30 2007-01-11 Bristol-Myers Squibb Pharma Company Hydrazide conjugates as imaging agents
US7824659B2 (en) 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
US20070098640A1 (en) * 2005-11-02 2007-05-03 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography
US9149545B2 (en) * 2005-11-02 2015-10-06 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography and methods for making same
EP1991577A2 (en) 2006-01-31 2008-11-19 Parkinson, John F. Modulation of mdl-1 activity for treatment of inflammatory disease
WO2009108376A2 (en) 2008-02-29 2009-09-03 Lantheus Medical Imaging, Inc. Contrast agents for applications including perfusion imaging
EP2296550B1 (en) * 2008-07-07 2018-03-28 Koninklijke Philips N.V. K-edge imaging
KR20160030589A (ko) 2009-04-15 2016-03-18 랜티우스 메디컬 이메징, 인크. 아스코르브산을 사용한 방사성 약제 조성물의 안정화
WO2011035140A1 (en) 2009-09-18 2011-03-24 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of contrast moieties to the lungs
DK3323810T3 (da) 2010-02-08 2022-03-28 Lantheus Medical Imaging Inc Automatiseret reaktionssystem, kassette og indretning til syntese af billeddannelsesmidler
EP2540321A1 (en) 2011-06-30 2013-01-02 Bayer Intellectual Property GmbH Bis Tridentate W3O2 Clusters for X-Ray imaging
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
EP2733148A1 (en) 2012-11-15 2014-05-21 Bayer Pharma Aktiengesellschaft Tungsten complexes with di-dentate ligands
JP6549554B2 (ja) 2013-03-15 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア コレステロール流出を刺激する、減少した毒性を有するペプチド

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US468759A (en) 1892-02-09 Gabeiel a
US3860611A (en) * 1972-01-19 1975-01-14 Du Pont Macrocyclic polyether polyols and condensation polymers derived therefrom
US3763188A (en) * 1972-01-19 1973-10-02 Du Pont Spiro(1,1-polyethylenedi(oxymethyl))-3-oxetanes
US3952015A (en) * 1973-11-12 1976-04-20 Carl George Krespan Macrocyclic compounds having oxa and aza linkages in the ring and containing spirooxetane groups
US4079124A (en) * 1976-04-21 1978-03-14 Medi-Physics, Inc. Method of preparing X-ray contrast media containing ores of hafnium, tantalum and tungsten
US4176173A (en) * 1977-07-18 1979-11-27 Medi-Physics, Inc. Radiographic compositions
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4652519A (en) 1983-02-03 1987-03-24 Yeda Research And Development Company Limited Bifunctional chelating agents and process for their production
US4826673A (en) 1985-01-09 1989-05-02 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
CA1282069C (en) 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
JP2833766B2 (ja) 1987-07-16 1998-12-09 ニユコメド・アクシエセルカペト アミノポリカルボン酸およびその誘導体
FR2630547A1 (fr) * 1988-04-22 1989-10-27 Centre Nat Rech Scient Marquage froid de molecules de nature peptidique ou proteique
US5260050A (en) * 1988-09-29 1993-11-09 Ranney David F Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
EP0361960A3 (en) * 1988-09-29 1992-01-02 RANNEY, David F. Methods and compositions for magnetic resonance imaging
GB9006977D0 (en) * 1990-03-28 1990-05-23 Nycomed As Compositions
US5186923A (en) * 1990-10-10 1993-02-16 Brigham And Womens Hospital Enhancement of cellular accumulation of lipophilic cationic organometallic compounds by reduction of intramembrane potential
AU670029B2 (en) * 1991-08-05 1996-07-04 Mallinckrodt Medical, Inc. Heavy metal clusters for use as imaging agents

Also Published As

Publication number Publication date
AU645796B2 (en) 1994-01-27
CA2079212A1 (en) 1991-09-29
DK0521977T3 (da) 1996-09-30
LT3535B (en) 1995-11-27
LV10056A (lv) 1994-05-10
JPH06507147A (ja) 1994-08-11
FI924297A0 (fi) 1992-09-25
NO923739L (no) 1992-11-06
HU9203086D0 (en) 1992-12-28
ATE142508T1 (de) 1996-09-15
US5458869A (en) 1995-10-17
HK219596A (en) 1997-01-03
GB9006977D0 (en) 1990-05-23
NO923739D0 (no) 1992-09-25
EP0521977A1 (en) 1993-01-13
WO1991014460A1 (en) 1991-10-03
DE69122092T2 (de) 1997-03-06
FI924297L (fi) 1992-09-25
FI924297A7 (fi) 1992-09-25
LV10056B (en) 1995-02-20
LTIP609A (en) 1994-12-27
AU7557891A (en) 1991-10-21
EP0645146A1 (en) 1995-03-29
US5614168A (en) 1997-03-25
EP0521977B1 (en) 1996-09-11
DE69122092D1 (de) 1996-10-17
SG43931A1 (en) 1997-11-14
HUT69168A (en) 1995-08-28

Similar Documents

Publication Publication Date Title
ES2091323T3 (es) Medios de contraste.
GR3005457T3 (es)
AU591309B2 (en) Taxol derivatives, their preparation and pharmaceutical compositions containing them
ATE38672T1 (de) 7-oxabicycloheptan aminosubstituierte prostaglandinaehnliche verbindungen.
ATE222244T1 (de) Mono -und multimere verbindungen mit erhöhter relaxation
DE69430611D1 (de) Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel
RU94042922A (ru) Новые соединения, способы их получения, фармацевтическая композиция
RU95112465A (ru) Пирановые соединения, фармацевтическая композиция, способ получения и промежуточные соединения
MX9301032A (es) Compuestos farmaceuticos y procedimento para su preparacion
RU92016591A (ru) Производные пиримидин нуклеозида
FI841555A0 (fi) Sjaelvutjaemnande polermedelskompositioner och daeri anvaendbara polymerkompositioner.
GT199900154A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
AU5670690A (en) Lysolecithin derivatives for treating autoimmune diseases
DK0471718T3 (da) Paracetamolholdigt farmaceutisk præparat
ES472640A1 (es) Procedimiento para preparar seudotrisacaridos
JPS5234923A (en) Novel antimicrobial agents for non-medical use
ATE161732T1 (de) In cyclodextrinen eingeschlossene steroide
ATE92070T1 (de) Azachromanderivate.
KR950014110A (ko) 사이클로프로판 유도체 및 이를 포함하는 항바이러스제
DE3769287D1 (de) Heilmittel gegen leishmaniose.
IL70082A0 (en) 1-aroyl-5-oxo-2-pyrrolidinepropanoic acids and salts and esters thereof,their preparation and pharmaceutical compositions containing them
IL96160A0 (en) Process for preparing(1r,2r)-2-(3-pyridyl)tetrahydrothiopyran-2-carbothioamide 1-oxides,the(1r,2r)-2-(3-pyridyl)tetrahydrothiopyran-2-carbothioamide 1-oxides thereby obtained and pharmaceutical compositions containing them
Seo Recommendations for the Improvement of the Medical Licensing Examination
FR2385703A1 (fr) Nouveaux derives d'imidazole et complexes metalliques de ceux-ci, procede de preparation desdits derives et application sous forme d'agents fongicides
ES2078380T3 (es) Oligofosfatos de accion antiviral.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 521977

Country of ref document: ES